

PRODUCT: LX-2343**ALTERNATE NAMES:** N-(benzo[d][1,3]dioxol-5-yl)-2-(N-(5-chloro-2-methoxyphenyl)phenylsulfonamido)acetamide**CATALOG NUMBER:** B2120-5,25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₂₂H₁₉ClN₂O₆S**MOLECULAR WEIGHT:** 474.91**CAS NUMBER:** 333745-53-2**APPEARANCE:** Crystalline solid**SOLUBILITY:** DMSO**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20 °C. Protect from air and light

DESCRIPTION: LX-2343 is a neuroprotective agent for the treatment of Alzheimer's disease. LX2343 ameliorates cognitive dysfunction in APP/PS1 transgenic mice via both Aβ production inhibition and clearance promotion. LX2-343 dose-dependently decreases Aβ accumulation in HEK293-APP_{sw} and CHO-APP cells, and promotes Aβ clearance in SH-SY5Y cells and primary astrocytes. The anti-amyloid effects of LX2343 are attributed to suppressing JNK-mediated APP^{Thr668} phosphorylation, thus inhibiting APP cleavage on one hand, and inhibiting BACE1 enzymatic activity with an IC₅₀ value of 11.43±0.36 μmol/L, on the other hand.

REFERENCE: Guo, X. D., *et al.* (2016). *Acta Pharmacol. Sin.* **37**, 1281-1297.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

BMS-299897 (**9606**)
BMS-708163 (**B1622**)
Compound 34 (**1898**)
Compound E (**1949**)
DAPT (**1855**)
DBZ (**2649**)
L-685,458 (**1713**)
LY-411575 (**2648**)
LY2886721 (**2299**)
LY2811376 (**B1606**)
MK-0752 (**B1980**)
MK-8931 (**B1315**)
RO4929097 (**2011**)
Semagacestat (**2430**)

USAGE: **FOR RESEARCH USE ONLY! Not to be used in humans**